6JUT

Crystal structure of ZAK in complex with compound 6k

Summary for 6JUT

• Entry DOI: 10.2210/pdb6jut/pdb
• Descriptor: Mitogen-activated protein kinase kinase kinase MLT, ~{N}-[2,4-bis(fluoranyl)-3-[4-(3-methoxy-1~{H}-pyrazolo[3,4-b]pyridin-5-yl)-1,2,3-triazol-1-yl]phenyl]-3-bromanyl-benzenesulfonamide (3 entities in total)
• Functional Keywords: zak, inhibitor, structural protein
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 35899.85

Authors

Kong, L.L.,Yun, C.H. (deposition date: 2019-04-15, release date: 2019-07-24, Last modification date: 2023-11-22)

Primary citation

Yang, J.,Shibu, M.A.,Kong, L.,Luo, J.,BadrealamKhan, F.,Huang, Y.,Tu, Z.C.,Yun, C.H.,Huang, C.Y.,Ding, K.,Lu, X.
Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-alpha Motif Kinase (ZAK) Inhibitors.
J.Med.Chem., 63:2114-2130, 2020

PubMed Abstract: ZAK is a new promising target for discovery of drugs with activity against antihypertrophic cardiomyopathy (HCM). A series of 1,2,3-triazole benzenesulfonamides were designed and synthesized as selective ZAK inhibitors. One of these compounds, binds tightly to ZAK protein ( = 8.0 nM) and potently suppresses the kinase function of ZAK with single-digit nM (IC = 4.0 nM) and exhibits excellent selectivity in a KINOMEscan screening platform against a panel of 403 wild-type kinases. This compound dose dependently blocks p38/GATA-4 and JNK/c-Jun signaling and demonstrates promising in vivo anti-HCM efficacy upon oral administration in a spontaneous hypertensive rat (SHR) model. Compound may serve as a lead compound for new anti-HCM drug discovery.

PubMed: 31244114
DOI: 10.1021/acs.jmedchem.9b00664

Experimental method

X-RAY DIFFRACTION (2.1 Å)